On September 9, Cytokinetics rose 5.1% in regular trading, trading at $76.32/share, with turnover of approximately $84.73 million. The rally reflects sustained momentum following a series of positive clinical catalysts.

On the news front, the company recently presented full results from its pivotal Phase 3 ACACIA-HCM trial in a Late Breaking session at the European Society of Cardiology Congress. Aficamten successfully met both co-primary endpoints — KCCQ-CSS and maximal exercise capacity — in patients with symptomatic non-obstructive hypertrophic cardiomyopathy over 36 weeks, with no new safety signals identified. The results were simultaneously published in The New England Journal of Medicine. Cytokinetics plans to submit a supplemental New Drug Application to the FDA in Q4, seeking to expand aficamten's approved indication to adult non-obstructive HCM patients. RBC Capital Markets previously estimated this label expansion could add approximately $1.3 billion in U.S. revenue. Meanwhile, the commercial launch of Myqorzo for obstructive HCM continues to gain traction, and the company has announced participation in upcoming September investor conferences.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)